Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fuzuloparib plus abiraterone/prednisone versus placebo plus abiraterone/prednisone in first-line metastatic castration-resistant prostate cancer
2020-006063-28Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Fuzuloparib + abiraterone acetate + prednisone with Placebo + abiraterone acetate + prednisone (2 arms). Primary endpoint: Radiographic progression-free survival. Started May 2021; status: active.
02
Drugs
fluzoparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2020-006063-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006063-28.